Skip to main content

Table 3 Pharmacokinetic parameters of NB-360 after oral and intravenous application in mouse, rat and beagle dog

From: A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice

Parameter

Mouse

Rat

Dog

Dose i.v. (μmol/kg)

2

2

2

Dose p.o. (μmol/kg)

6

6

2

Clearance after i.v. application (ml/min/kg)

16

52

0.4

Terminal half-life after i.v. application (hours)

3.6

2.7

36.2

Vol. of Distribution (l/kg)

4.6

10.2

0.9

Oral Bioavailability (%)

37

92

62

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326